BRKR Stock Overview
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Bruker Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$54.91 |
| 52 Week High | US$84.84 |
| 52 Week Low | US$53.79 |
| Beta | 1.13 |
| 1 Month Change | -11.86% |
| 3 Month Change | -21.75% |
| 1 Year Change | -11.21% |
| 3 Year Change | 24.71% |
| 5 Year Change | 65.14% |
| Change since IPO | 138.09% |
Recent News & Updates
Recent updates
Is Bruker (NASDAQ:BRKR) Using Too Much Debt?
Oct 23
Here's Why Bruker (NASDAQ:BRKR) Has Caught The Eye Of Investors
Sep 25Does This Valuation Of Bruker Corporation (NASDAQ:BRKR) Imply Investors Are Overpaying?
Aug 09Is Now The Time To Look At Buying Bruker Corporation (NASDAQ:BRKR)?
Jul 27Bruker (NASDAQ:BRKR) Has A Pretty Healthy Balance Sheet
Jul 11If EPS Growth Is Important To You, Bruker (NASDAQ:BRKR) Presents An Opportunity
Jun 26Is It Time To Consider Buying Bruker Corporation (NASDAQ:BRKR)?
Apr 25These 4 Measures Indicate That Bruker (NASDAQ:BRKR) Is Using Debt Reasonably Well
Apr 07Bruker (NASDAQ:BRKR) Ticks All The Boxes When It Comes To Earnings Growth
Feb 20Why Bruker Corporation (NASDAQ:BRKR) Could Be Worth Watching
Jan 17Is Bruker (NASDAQ:BRKR) Using Too Much Debt?
Dec 30Should You Think About Buying Bruker Corporation (NASDAQ:BRKR) Now?
Oct 16Here's Why We Think Bruker (NASDAQ:BRKR) Is Well Worth Watching
Oct 03Estimating The Intrinsic Value Of Bruker Corporation (NASDAQ:BRKR)
Sep 19Is Bruker (NASDAQ:BRKR) Using Too Much Debt?
Sep 05Bruker Corporation: Upside Is Limited From Here
Aug 24Bruker declares $0.05 dividend
Aug 12Why Bruker Corporation (NASDAQ:BRKR) Could Be Worth Watching
Jul 12Bruker announces three new GHz NMR systems orders
Jul 11Here's Why We Think Bruker (NASDAQ:BRKR) Might Deserve Your Attention Today
Jun 29Calculating The Intrinsic Value Of Bruker Corporation (NASDAQ:BRKR)
Jun 15Here's Why Bruker Is A Strong Buy
Jun 09Bruker (NASDAQ:BRKR) Could Easily Take On More Debt
Jun 02Is It Too Late To Consider Buying Bruker Corporation (NASDAQ:BRKR)?
Apr 12Shareholder Returns
| BRKR | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -7.9% | -6.9% | -2.4% |
| 1Y | -11.2% | -18.6% | 4.1% |
Return vs Industry: BRKR exceeded the US Life Sciences industry which returned -18.6% over the past year.
Return vs Market: BRKR underperformed the US Market which returned 4.1% over the past year.
Price Volatility
| BRKR volatility | |
|---|---|
| BRKR Average Weekly Movement | 4.4% |
| Life Sciences Industry Average Movement | 7.4% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in US Market | 14.2% |
| 10% least volatile stocks in US Market | 2.7% |
Stable Share Price: BRKR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: BRKR's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 8,525 | Frank Laukien | https://www.bruker.com |
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits.
Bruker Corporation Fundamentals Summary
| BRKR fundamental statistics | |
|---|---|
| Market Cap | US$8.06b |
| Earnings (TTM) | US$319.10m |
| Revenue (TTM) | US$2.71b |
25.3x
P/E Ratio3.0x
P/S RatioIs BRKR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BRKR income statement (TTM) | |
|---|---|
| Revenue | US$2.71b |
| Cost of Revenue | US$1.31b |
| Gross Profit | US$1.40b |
| Other Expenses | US$1.08b |
| Earnings | US$319.10m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Nov 02, 2023
| Earnings per share (EPS) | 2.17 |
| Gross Margin | 51.64% |
| Net Profit Margin | 11.76% |
| Debt/Equity Ratio | 98.3% |
How did BRKR perform over the long term?
See historical performance and comparison